<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123769</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F351-201901</org_study_id>
    <nct_id>NCT04123769</nct_id>
  </id_info>
  <brief_title>Study on PK of Hydronidone in Patients and Special Population</brief_title>
  <official_title>Pharmacokinetics of Hydronidone Capsules in Patients With Chronic Hepatitis B Complicated With Liver Fibrosis and Mild Hepatic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target&#xD;
           patients (patients with chronic viral hepatitis b with liver fibrosis) and special&#xD;
           population (patients with mild liver dysfunction).&#xD;
&#xD;
        2. To evaluate the effect of oral Hydronidone capsule on QT/QTc in patients with chronic&#xD;
           viral hepatitis b accompanied by hepatic fibrosis and mild hepatic dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Actual">January 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>QT/QTc</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hepatitis b &amp; Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydronidone</intervention_name>
    <description>First take Hydronidone capsule, single-dose and then Multiple-dose</description>
    <arm_group_label>Drug group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years (including 18 and 65 years);&#xD;
&#xD;
          2. BMI 18-26 (including 18 and 26) [BMI= weight (kg)/height 2 (m2)];&#xD;
&#xD;
          3. History of chronic hepatitis b, HBsAg positive ≥6 months;&#xD;
&#xD;
          4. ALT &lt; 5 times ULN (standard upper limit);&#xD;
&#xD;
          5. TBiL &lt; 2 times ULN (standard upper limit);&#xD;
&#xD;
          6. ALP &lt; 1.5 times ULN (standard upper limit);&#xD;
&#xD;
          7. Liver elastic hardness test confirmed significant liver fibrosis (LSM≥ 7.3kpa);&#xD;
&#xD;
          8. Scores assessed by child-pugh system are 5 or 6;&#xD;
&#xD;
          9. Patients currently receiving antiviral treatment with entecavir;&#xD;
&#xD;
         10. The subject (or his/her partner) has no pregnancy plan during and within 6 months&#xD;
             after the trial and voluntarily takes effective physical contraception and has no&#xD;
             sperm or egg donation plan;&#xD;
&#xD;
         11. Before the trial, I have had a detailed understanding of the nature, significance,&#xD;
             possible benefits, possible inconveniences and potential risks of the trial, and I&#xD;
             have volunteered to participate in the clinical trial. I am able to communicate well&#xD;
             with the investigator, comply with the requirements of the whole study, and have&#xD;
             signed a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who do not meet any of the inclusion criteria;&#xD;
&#xD;
          2. (consultation) participants in clinical trials of other drugs in recent 3 months;&#xD;
&#xD;
          3. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common&#xD;
             liver enzyme inducers: barbiturates (phenobarbital is the most common), carbamazepine,&#xD;
             aminoximate, griseofulvin, aminopropyl ester, phenytoin, gromitol, rifampin,&#xD;
             dexamethasone; Common liver enzyme inhibitors: chlorpromazine, cimetidine,&#xD;
             ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide);&#xD;
&#xD;
          4. (consultation) select those who drank excessive amounts of tea, coffee or caffeinated&#xD;
             beverages (more than 8 cups a day, 1 cup =250mL) every day during the first three&#xD;
             months; Or from the screening to -1 days after admission, intake of any food or drink&#xD;
             containing caffeine and xanthine (such as coffee, strong tea, chocolate, etc.) and&#xD;
             other special diet that affects the absorption, distribution, metabolism and excretion&#xD;
             of drugs;&#xD;
&#xD;
          5. (consultation) patients who had taken food or drinks containing enzymes that can&#xD;
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,&#xD;
             orange juice and other compounds rich in flavonoids or citrus glycosides) before&#xD;
             admission were screened.&#xD;
&#xD;
          6. (consultation) screening: drinking more than 14 standard units of alcohol per week in&#xD;
             the first 3 months (1 standard unit contains 14g of alcohol, such as 360 mL beer or 45&#xD;
             mL spirits with 40% alcohol or 150 mL wine); Or cannot abstain from alcohol during the&#xD;
             test period; Or taking any alcohol products within 24 hours before the first dose of&#xD;
             the study;&#xD;
&#xD;
          7. (consultation) select those who smoke more than 5 cigarettes per day within the first&#xD;
             3 months, or cannot stop using any tobacco products during the trial; Screening for&#xD;
             smoking or using any tobacco products up to admission;&#xD;
&#xD;
          8. (consultation) previous history of drug abuse and drug abuse;&#xD;
&#xD;
          9. (consultation) patients with upper gastrointestinal massive bleeding or active peptic&#xD;
             ulcer within the first 3 months were enrolled;&#xD;
&#xD;
         10. (consultation) patients with serious diseases of cardiovascular, pulmonary, renal,&#xD;
             endocrine, nervous and blood systems and mental disorders;&#xD;
&#xD;
         11. (consultation) allergy: if allergic to two or more drugs or food; Lactose intolerant;&#xD;
&#xD;
         12. AFP &gt; 100 μg /L;&#xD;
&#xD;
         13. B ultrasound showed obvious space-occupying lesions in the liver, suggesting tumor;&#xD;
&#xD;
         14. Patients with decompensated liver cirrhosis;&#xD;
&#xD;
         15. Patients with malignant tumors;&#xD;
&#xD;
         16. Received non-entecavir nucleoside analogues or interferon antiviral therapy within 3&#xD;
             months before inclusion;&#xD;
&#xD;
         17. Pregnant and/or lactating women;&#xD;
&#xD;
         18. Subjects who are legally disabled according to the law of the People's Republic of&#xD;
             China on the protection of disabled persons (April 2008);&#xD;
&#xD;
         19. Alcohol breath test results greater than 0.0mg/100mL;&#xD;
&#xD;
         20. Positive urine drug screening;&#xD;
&#xD;
         21. Patients with suspected poor compliance;&#xD;
&#xD;
         22. The investigator considers that there are any circumstances that may affect the&#xD;
             subject's informed consent or adherence to the study protocol, or participation in the&#xD;
             study may affect the results of the study or their own safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical ethics committee of wuhan infectious disease hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

